Steven Cohen Altimmune, Inc. Transaction History

Point72 Asset Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$8.22 - $13.81 $10.2 Million - $17.1 Million	-1,238,900 Reduced 99.39%	7,600 $77,000
Q4 2023 Feb 14, 2024	BUY	$2.14 - $11.62 $2.67 Million - $14.5 Million	1,246,500 New	1,246,500 $14 Million
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $58,605 - $235,401	13,987 New	13,987 $59,000
Q2 2022 Aug 15, 2022	BUY	$3.94 - $11.77 $2.4 Million - $7.17 Million	609,100 New	609,100 $7.13 Million
Q3 2021 Nov 15, 2021	SELL	$8.43 - $16.81 $13.2 Million - $26.3 Million	-1,564,654 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$9.85 - $16.46 $15.4 Million - $25.8 Million	1,564,654 New	1,564,654 $15.4 Million

191

42.4M

1.05M

582K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $304M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.